Theratechnologies is developing a novel and targeted treatment platform in oncology based on new proprietary peptides targeting the sortilin receptor. The expression of the sortilin receptor has been documented in ovarian, triple negative breast, skin, lung, colorectal and pancreatic cancers, among others.
Targeting sortilin receptors could therefore lead to a selective delivery approach as well as a specific internalization of a number of anticancer agents that can be linked to these peptides. The use of this strategy would be a step towards personalized medicine for patients where only those likely to respond to the drug would first be identified and treated in this way, increasing the chance of a cure and minimizing health care costs.
New peptide-drug conjugates (PDC) generated through our platform are considered new chemical entities (NCEs) with pharmacodynamic and pharmacokinetic properties different from their parent compounds. These new anticancer agents should also induce less toxicity to non-cancerous cells that have no or only a fraction of sortilin receptors observed in some cancers.
Further preclinical research activities are being conducted using TH1904, our second investigational PDC (doxorubicin conjugate). In vitro and in vivo experiments using TH1904 have demonstrated results similar to those obtained with TH1902 and support the development of additional investigational compounds using our SORT1+ Technology™ that may help in the fight against cancer.
In vivo, TH1904 was better tolerated than free doxorubicin and caused more potent inhibition of human ovarian tumor xenografts grown in mice. These results strongly support the future clinical use of this platform to generate novel personalized therapeutics for specific targeting of sortilin-positive tumors.
SORT1+ Technology™ is a trademark of Theratechnologies Inc.